Associated tags: FDA, Jonathan Rothberg, Magnetic resonance imaging, Swoop, National Medal, DNA, Patient, Operating, MRI, Therapy, Intensive care medicine, Butterfly network, Hyperfine structure, Medical imaging, Health, Medical Devices, Research
Locations: UNITED STATES, NORTH AMERICA, CONNECTICUT
Retrieved on:
Wednesday, August 10, 2022
FDA,
High-dependency unit,
PST,
Interim,
CEO,
GLOBE,
Growth,
Geography,
Hospital,
Health,
Income,
Marketing,
Patient,
Paola Lattus,
DL,
Partnership,
Deep learning,
Decision-making,
Awareness,
Research,
Intensive care unit,
Magnetic resonance imaging,
Time,
Neuro,
MRI,
Adoption,
Video game,
Reinsurance,
Animal,
Renewable energy,
Medical imaging,
Swoop,
Hyperfine structure Revenues for the second quarter of 2022 were $1.533 million, compared to $0.358 million in the second quarter of 2021.
Key Points:
- Revenues for the second quarter of 2022 were $1.533 million, compared to $0.358 million in the second quarter of 2021.
- Gross margin for the second quarter of 2022 was $(0.165) million, compared to $(0.099) million in the second quarter of 2021.
- Research and development expenses for the second quarter of 2022 were $7.265 million, compared to $6.037 million in the second quarter of 2021.
- Sales, marketing, general, and administrative expenses for the second quarter of 2022 were $15.762 million, compared to $8.450 million in the second quarter of 2021.
MRI,
Paola Lattus,
Hyperfine structure,
High-dependency unit,
GLOBE,
Swoop,
FDA,
Investor,
Income,
Magnetic resonance imaging,
Patient,
Medical imaging GUILFORD, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop, the world's first FDA-cleared portable MRI system, today announced that it will report financial results for the second quarter 2022 on Wednesday, August 10, 2022.
Key Points:
- GUILFORD, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop, the world's first FDA-cleared portable MRI system, today announced that it will report financial results for the second quarter 2022 on Wednesday, August 10, 2022.
- Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- Those interested in listening to the audio webcast should register online here.
- Hyperfine, Inc. is the groundbreaking medical device company that created Swoop, the worlds first FDA-cleared portable MRI system.
Income,
Technology,
Element,
Conference,
Marketing,
US,
Security (finance),
The Lego Group,
U.S. Securities and Exchange Commission,
Hydrocephalus,
MRI,
CT,
Risk,
Patient,
Swoop,
Brain,
GLOBE,
COVID-19,
Diagnosis,
Magnetic resonance imaging,
Private Securities Litigation Reform Act,
LEGO,
Nasdaq,
Health,
Humanitarian use licenses,
Pressure,
Radiation exposure,
FDA,
Research,
Growth,
US FDA,
Software,
Caregiver,
Partnership,
Mission statement,
Medical imaging,
Hyperfine structure Hyperfine is an official partner with the Hydrocephalus Association (HA), the nations most widely respected organization dedicated to research and advocacy of hydrocephalus.
Key Points:
- Hyperfine is an official partner with the Hydrocephalus Association (HA), the nations most widely respected organization dedicated to research and advocacy of hydrocephalus.
- In short, pediatric head CT scans pose a significant health risk to children with hydrocephalus.
- Young people diagnosed with this life-threatening neurological condition require life-long brain monitoring, said Hyperfine Chief Medical Officer Dr. Khan Siddiqui.
- Hyperfine designed Swoop to enable rapid diagnosis and treatment of all patients regardless of income, resources, or location, pushing the boundaries of conventional imaging technology and expanding patient access to timely care.
FDA,
Patient,
CEO,
Caregiver,
Paola Lattus,
Adoption,
GLOBE,
Marketing,
COVID-19,
Growth,
Company,
U.S. Securities and Exchange Commission,
Interim,
Magnetic resonance imaging,
Partnership,
Humanitarian use licenses,
Investor,
Traction,
Technology,
Private Securities Litigation Reform Act,
High-dependency unit,
Board,
Leadership,
MRI,
Income,
Security (finance),
Conference,
Management,
Pharmaceutical industry,
Medical imaging,
Renewable energy,
Swoop,
Nasdaq,
Hyperfine structure GUILFORD, Conn., June 29, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), (“Hyperfine” or “the Company”), the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system™, today announced that Dave Scott will step down from his role as President, Chief Executive Officer (CEO), and Board Member for personal reasons, effective July 29, 2022. Scott Huennekens, who currently serves as Executive Chairperson of the Board, will succeed Mr. Scott as interim President and CEO, also effective July 29, 2022. The Company is engaging in a search for a long-term CEO as it continues to execute its business strategy focused on commercial expansion of the Swoop system. The Company will host a conference call to discuss the CEO transition today, June 29, 2022, at 4:30 PM Eastern Time.
Key Points:
- The Company will host a conference call to discuss the CEO transition today, June 29, 2022, at 4:30 PM Eastern Time.
- As interim President and CEO, Mr. Huennekens will oversee the ongoing expansion of Hyperfine to become a leading medical imaging provider.
- We wish him well as he addresses the personal reasons limiting his ability to continue as President and CEO of Hyperfine.
- I am disappointed to have to step back from my role as President and CEO of Hyperfine.
Paragon,
Mission statement,
Biomedical Research,
Neuroimaging,
Time,
Health,
Research,
Marketing,
Deep learning,
Income,
Artificial intelligence,
Partnership,
News,
Security (finance),
U.S. Securities and Exchange Commission,
City,
Nasdaq,
Â,
NIF,
US FDA,
Physician,
Quantum,
Monash University,
Growth,
GLOBE,
Patient,
Private Securities Litigation Reform Act,
Technology,
COVID-19,
Magnetic resonance imaging,
Diagnosis,
Population,
Radiation,
Department,
ICU,
Swoop,
MRI,
Medical imaging,
Radiology,
Hyperfine structure Hyperfine is pleased to announce the appointment of Quantum HealthCare as the companys distributor for Australia and New Zealand.
Key Points:
- Hyperfine is pleased to announce the appointment of Quantum HealthCare as the companys distributor for Australia and New Zealand.
- Quantum HealthCare General Manager Tiffany Chiew said, Quantum is very excited to be distributing Hyperfines mobile MRI technology in Australia and New Zealand.
- Australia and New Zealand have a population of 31 million people spread across a vast geographic area.
- Hyperfine, Inc. is the groundbreaking medical device company that created Swoop, the worlds first US FDA-cleared portable MRI system.
Magnetic resonance imaging,
Income,
Patient,
MRI,
Swoop,
ICU,
FDA,
Conference,
Interest,
High-dependency unit,
Paola Lattus,
CFO,
CEO,
GLOBE,
Medical imaging GUILFORD, Conn., May 25, 2022 (GLOBE NEWSWIRE) -- Hyperfine (Nasdaq: HYPR), the creator of Swoop, the world's first FDA-cleared portable MRI system, today announced that management will be presenting at the upcoming 2022 Jefferies Global Healthcare Conference in New York, New York.
Key Points:
- GUILFORD, Conn., May 25, 2022 (GLOBE NEWSWIRE) -- Hyperfine (Nasdaq: HYPR), the creator of Swoop, the world's first FDA-cleared portable MRI system, today announced that management will be presenting at the upcoming 2022 Jefferies Global Healthcare Conference in New York, New York.
- Dave Scott, President and CEO, and Alok Gupta, CFO, are scheduled to present onWednesday, June 8 at 4:00 PM EDT.
- Interested parties may access a live and archived webcast of the presentation on the Investors section of the companys website at: https://investors.hyperfine.io .
- Hyperfine, Inc. is the groundbreaking medical device company that created Swoop, the worlds first FDA-cleared portable MRI system.
Cyprus Securities and Exchange Commission,
Humanitarian use licenses,
Security (finance),
Private Securities Litigation Reform Act,
Partnership,
Growth,
COVID-19,
Nasdaq,
Technology,
Marketing,
Risk management Hyperfines actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events.
Key Points:
- Hyperfines actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events.
- These forward-looking statements include, without limitation, expectations about Hyperfines financial and operating results, the benefits of Hyperfines products and services, and Hyperfines future performance and its ability to implement its strategy.
- These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.
- Hyperfine cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made.
Retrieved on:
Wednesday, April 20, 2022
Magnetic resonance imaging,
Swoop,
Income,
MRI,
FDA,
GLOBE,
Hyperfine structure,
Paola Lattus,
Patient,
High-dependency unit,
Investor,
Medical imaging GUILFORD, Conn., April 20, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop, the world's first FDA-cleared portable MRI system, today announced that it will report financial results for the first quarter 2022 on Wednesday, May 11, 2022.
Key Points:
- GUILFORD, Conn., April 20, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop, the world's first FDA-cleared portable MRI system, today announced that it will report financial results for the first quarter 2022 on Wednesday, May 11, 2022.
- Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- Hyperfine, Inc. is the groundbreaking medical device company that created Swoop, the worlds first FDA-cleared portable MRI system.
- Swoop can be wheeled directly to the patients bedside, plugged into a standard electrical wall outlet, and controlled by an iPad.
Retrieved on:
Wednesday, March 23, 2022
Income,
Paola Lattus,
Investor,
MRI,
Patient,
FDA,
Magnetic resonance imaging,
Hyperfine structure,
Swoop,
GLOBE,
High-dependency unit,
Medical imaging GUILFORD, CT, March 03, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop, the world's first FDA-cleared portable MRI system, today announced that it will report financial results for the fourth quarter and full year 2021 on Wednesday, March 23, 2022.
Key Points:
- GUILFORD, CT, March 03, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop, the world's first FDA-cleared portable MRI system, today announced that it will report financial results for the fourth quarter and full year 2021 on Wednesday, March 23, 2022.
- Company management will host a corresponding conference call to discuss the financial results and provide a business update beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- Hyperfine, Inc. is the groundbreaking medical device company that created Swoop, the worlds first FDA-cleared portable MRI system.
- Swoop can be wheeled directly to the patients bedside, plugged into a standard electrical wall outlet, and controlled by an iPad.
